Abbott Laboratories (ABT)

58.30
0.01 0.03
NYSE : Health Technology
Prev Close 58.31
Open 58.04
Day Low/High 57.70 / 58.52
52 Wk Low/High 42.88 / 64.60
Volume 2.50M
Avg Volume 7.07M
Exchange NYSE
Shares Outstanding 1.75B
Market Cap 102.75B
EPS 0.30
P/E Ratio 280.19
Div & Yield 1.12 (1.82%)

Latest News

Weekly Roundup

Markets give up some gains Thursday and Friday, ahead of heavy earnings next week.

Dow Declines Slightly as S&P 500, Nasdaq Post Modest Gains

Dow Declines Slightly as S&P 500, Nasdaq Post Modest Gains

Stocks finish mixed on Wednesday amid a sharp decline in IBM shares.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts look at banks, three sections to trade, and REITs.

Abbott CEO: New Glucose Device's U.S. Launch 'Has Gone Exceptionally Well'

Abbott CEO: New Glucose Device's U.S. Launch 'Has Gone Exceptionally Well'

FreeStyle Libre already has over 50,000 users in the U.S. since being approved for sale in the U.S. last September.

Jim's Daily Rundown

Jim discusses latest results for Abbott Labs, Goldman Sachs and more.

Abbott Labs Reports Top and Bottom Beat

Overall, it was a very solid quarter by Abbott.

Abbott Laboratories Tops Q1 Earnings Estimates, Issues Full Year Guidance

Abbott Laboratories Tops Q1 Earnings Estimates, Issues Full Year Guidance

Abbott sees full year earnings of between $2.80 to $2.90 a share after a solid first quarter that topped Wall Street forecasts.

Why I'm Not Piling 'All In' to the Banks: Market Recon

Why I'm Not Piling 'All In' to the Banks: Market Recon

Market reactions have ranged anywhere from lackluster to outright negative. What gives?

IBM, Morgan Stanley, Southwest - 5 Things You Must Know Before the Market Opens

IBM, Morgan Stanley, Southwest - 5 Things You Must Know Before the Market Opens

U.S. stock futures rise modestly; IBM tumbles after it reports a weaker-than-expected profit margin; the NTSB says the blown engine on a Southwest plane had 'metal fatigue.'

Glucose Monitoring Device in Focus as Abbott Preps to Unveil Earnings

Glucose Monitoring Device in Focus as Abbott Preps to Unveil Earnings

Abbott's Freestyle Libre in September secured FDA approval and in January, the company said the device had received reimbursement from the Centers for Medicare & Medicaid Services.

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

Is Newell Brands Worth the Fight?: Cramer's Top Takeaways

Is Newell Brands Worth the Fight?: Cramer's Top Takeaways

Not every battle is worth fighting, says Jim Cramer. That's especially true if you own shares of Newell Brands.

Vistra Energy Generating Cash Flow: Cramer's Top Takeaways

Vistra Energy Generating Cash Flow: Cramer's Top Takeaways

Curtis Morgan, president and CEO of Vistra Energy, talks to Jim Cramer about the outlook for coal and renewables.

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.

Seven Portfolio Companies Report This Week

Latest results due from UnitedHealth, Goldman Sachs, Abbott and more.

Jim's Daily Rundown

Today, Jim discusses Raytheon, tensions in Syria, bank earnings, Kohl's, Nordstrom and more!

Weekly Roundup

The markets bounced back on easing trade tensions and the banks kicked off first-quarter earnings season.

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars

The company will not need to worry about Biogen and Samsung Bioepis launching a biosimilar to challenge the reign of its blockbuster arthritis drug until 2023 after the three companies settled patent actions.

Initiating Position in UnitedHealth; Adding to 3M and Abbott Labs

We have long been fans of UNH as the company is a strong defensive name.

Abbott Initiates Trial To Evaluate Improved Survival And Outcomes With The CardioMEMS Monitor

Abbott Initiates Trial To Evaluate Improved Survival And Outcomes With The CardioMEMS Monitor

- THE CARDIOMEMS™ HF SYSTEM IS THE FIRST AND ONLY FDA-APPROVED HEART FAILURE MONITOR PROVEN TO SIGNIFICANTLY REDUCE HEART FAILURE HOSPITAL ADMISSIONS AND IMPROVE QUALITY OF LIFE

Weekly Roundup

Fears of a trade war and a Fed rate hike marked a volatile week.

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu

Here's what you need to know now for Thursday, March 22.

Abbott's MitraClip Therapy Receives National Reimbursement In Japan To Treat Patients With Mitral Regurgitation

Abbott's MitraClip Therapy Receives National Reimbursement In Japan To Treat Patients With Mitral Regurgitation

- National reimbursement adds the device into Japan's health insurance system, which enables greater access for patients

Jim Cramer: We've Got a Battle Ahead of Us, But the Fed Might Resolve It

Jim Cramer: We've Got a Battle Ahead of Us, But the Fed Might Resolve It

Sectors are saying different things about rates, but new Fed chief Jerome Powell could provide clarity at his first press conference on Wednesday.

Weekly Roundup

White House gets new economic adviser.

Merck, Phillips 66, Five Below, Cintas: 'Mad Money' Lightning Round

Merck, Phillips 66, Five Below, Cintas: 'Mad Money' Lightning Round

Jim Cramer focuses on Merck, Eli Lilly, Abbott Labs, Phillips 66, Five Below, and Cintas in the Lightning Round.

TheStreet Quant Rating: B- (Buy)